National cooperative group trials

Robert S. DiPaola, Ian M. Thompson, Daniel P. Petrylak, Matthew R. Smith, Michael A Carducci, Joel B. Nelson, Ian M. Thompson

Research output: Contribution to journalArticle

Abstract

Now is the time to answer critical questions in the management of prostate cancer through enrollment in high-priority national phase 3 clinical trials. Studies of systemic therapy before and after local therapy are vitally important to determine whether early systemic interventions might delay cancer progression. Chemotherapy must be studied in earlier disease progression. Novel targeted therapies, such as vaccine therapy, angiogenesis inhibitors, and newer microtubule targeting agents, should be studied in all stages of progression. Despite these needs and the availability of systemic therapies, accrual to trials has been lagging. This article reviews the national cooperative group clinical trials, whether currently open or planned, and suggests practical strategies to improve accrual.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalUrology
Volume65
Issue number5 SUPPL.
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Active Immunotherapy
Phase III Clinical Trials
Angiogenesis Inhibitors
Therapeutics
Microtubules
Disease Progression
Prostatic Neoplasms
Clinical Trials
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

DiPaola, R. S., Thompson, I. M., Petrylak, D. P., Smith, M. R., Carducci, M. A., Nelson, J. B., & Thompson, I. M. (2005). National cooperative group trials. Urology, 65(5 SUPPL.), 23-29. https://doi.org/10.1016/j.urology.2005.03.042

National cooperative group trials. / DiPaola, Robert S.; Thompson, Ian M.; Petrylak, Daniel P.; Smith, Matthew R.; Carducci, Michael A; Nelson, Joel B.; Thompson, Ian M.

In: Urology, Vol. 65, No. 5 SUPPL., 05.2005, p. 23-29.

Research output: Contribution to journalArticle

DiPaola, RS, Thompson, IM, Petrylak, DP, Smith, MR, Carducci, MA, Nelson, JB & Thompson, IM 2005, 'National cooperative group trials', Urology, vol. 65, no. 5 SUPPL., pp. 23-29. https://doi.org/10.1016/j.urology.2005.03.042
DiPaola RS, Thompson IM, Petrylak DP, Smith MR, Carducci MA, Nelson JB et al. National cooperative group trials. Urology. 2005 May;65(5 SUPPL.):23-29. https://doi.org/10.1016/j.urology.2005.03.042
DiPaola, Robert S. ; Thompson, Ian M. ; Petrylak, Daniel P. ; Smith, Matthew R. ; Carducci, Michael A ; Nelson, Joel B. ; Thompson, Ian M. / National cooperative group trials. In: Urology. 2005 ; Vol. 65, No. 5 SUPPL. pp. 23-29.
@article{69c8924f188b4472a9b8e8af318d41cd,
title = "National cooperative group trials",
abstract = "Now is the time to answer critical questions in the management of prostate cancer through enrollment in high-priority national phase 3 clinical trials. Studies of systemic therapy before and after local therapy are vitally important to determine whether early systemic interventions might delay cancer progression. Chemotherapy must be studied in earlier disease progression. Novel targeted therapies, such as vaccine therapy, angiogenesis inhibitors, and newer microtubule targeting agents, should be studied in all stages of progression. Despite these needs and the availability of systemic therapies, accrual to trials has been lagging. This article reviews the national cooperative group clinical trials, whether currently open or planned, and suggests practical strategies to improve accrual.",
author = "DiPaola, {Robert S.} and Thompson, {Ian M.} and Petrylak, {Daniel P.} and Smith, {Matthew R.} and Carducci, {Michael A} and Nelson, {Joel B.} and Thompson, {Ian M.}",
year = "2005",
month = "5",
doi = "10.1016/j.urology.2005.03.042",
language = "English (US)",
volume = "65",
pages = "23--29",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - National cooperative group trials

AU - DiPaola, Robert S.

AU - Thompson, Ian M.

AU - Petrylak, Daniel P.

AU - Smith, Matthew R.

AU - Carducci, Michael A

AU - Nelson, Joel B.

AU - Thompson, Ian M.

PY - 2005/5

Y1 - 2005/5

N2 - Now is the time to answer critical questions in the management of prostate cancer through enrollment in high-priority national phase 3 clinical trials. Studies of systemic therapy before and after local therapy are vitally important to determine whether early systemic interventions might delay cancer progression. Chemotherapy must be studied in earlier disease progression. Novel targeted therapies, such as vaccine therapy, angiogenesis inhibitors, and newer microtubule targeting agents, should be studied in all stages of progression. Despite these needs and the availability of systemic therapies, accrual to trials has been lagging. This article reviews the national cooperative group clinical trials, whether currently open or planned, and suggests practical strategies to improve accrual.

AB - Now is the time to answer critical questions in the management of prostate cancer through enrollment in high-priority national phase 3 clinical trials. Studies of systemic therapy before and after local therapy are vitally important to determine whether early systemic interventions might delay cancer progression. Chemotherapy must be studied in earlier disease progression. Novel targeted therapies, such as vaccine therapy, angiogenesis inhibitors, and newer microtubule targeting agents, should be studied in all stages of progression. Despite these needs and the availability of systemic therapies, accrual to trials has been lagging. This article reviews the national cooperative group clinical trials, whether currently open or planned, and suggests practical strategies to improve accrual.

UR - http://www.scopus.com/inward/record.url?scp=18244363087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244363087&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.03.042

DO - 10.1016/j.urology.2005.03.042

M3 - Article

C2 - 15885277

AN - SCOPUS:18244363087

VL - 65

SP - 23

EP - 29

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5 SUPPL.

ER -